https://doi.org/10.55788/d0a77cf5
The largest genetic study to date in psoriasis was a recent meta-analysis of 18 genome-wide association studies totalling 36,466 cases of psoriasis and 458,078 controls, which identified 109 genetic loci associated with psoriasis [1,2]. These loci are responsible for the TNF/NF-ÎșB, IL-17/IL-23, and aryl hydrocarbon receptor pathways, as well as pathways responsible for antigen presentation and innate immunity related to viral antigens. Furthermore, this study showed that cell types such as fibroblasts, melanocytes, and endothelial, lymphatic, and eccrine cells are also implicated in psoriasis [2]. In pustular psoriasis, multiple genes have been identified in recent years, implicating the IL-1, IL-36, and IL-26 pathways [3].
How can the assessment of genetics be useful to doctors? Firstly, genetic signatures could be predictive of the development of psoriatic arthritis. To this end, a machine-learning model using around 200 gene loci has been developed to predict psoriatic arthritis, with an AUROC of approximately 80% [4]. âHopefully, in the near future, you will open up your electronic medical records seeing a warning message that your patient is at risk,â said Prof. Liao [1].
Furthermore, genetics has been used to predict responses to therapies. Patients with psoriasis who are positive for HLA-C*06:02 have improved responses to ustekinumab, whereas patients who are negative for HLA-C*06:02 have increased chances to respond to adalimumab, with mutations in the HLA-DR binding groove responsible for the development of anti-drug antibodies to adalimumab and discontinuations of therapy [5â7].
Genetics can also be used to determine the relationship between psoriasis and environmental triggers. âHistorically, factors like obesity, biomechanical stress, diet, various infections, smoking, and medications are all associated with the onset or worsening of psoriasis, but these have been largely cohort or observational studies,â said Prof. Liao [1]. âIt is hard to say whether these factors are causal or merely associated.â The genetic tool called Mendelian randomisation can help shed light on the causal nature of various associations [8]. This approach has led to âincreasing evidence that not only obesity, BMI, and smoking, but also Crohnâs disease, type 2 diabetes, and depression are causally linked to the development of psoriasis, and, similarly, vitamin D levels, a personâs fruit intake, and educational attainment are protective against the development of psoriasis,â said Prof. Liao [1,8].
Finally, advances in the immunology of psoriasis also indicate that the current model of psoriasis immunology should be expanded. âWe can now build on the basic model of just T cells, antigen-presenting cells, and keratinocytes with our now more expanded understanding of fibroblasts, endothelial cells, and other cell types,â said Prof. Liao [1]. âWe have also seen that psoriasis may be triggered by group A Streptococcus, as well as self-lipid, wheat, tobacco, and microbial antigensâ [9].
- Liao W. Advances in genetics and immunology of psoriasis. IFPA Conference 2024, 27â29 June, Stockholm, Sweden.
- Dand N, et al. medRxiv. 2023.
- Baldo A, et al. J Exp Med. 2024;221(5):e20231464.
- Patrick MT, et al. Nat Commun. 2018;9(1):4178.
- van Vugt LJ, et al. JAMA Dermatol. 2019 Jun 1;155(6):708-715.
- Dand N, et al. J Allergy Clin Immunol. 2019 ;143(6):2120-2130.
- Tsakok T, et al. JCI Insight. 2023;8(4):e156643.
- Jin JQ, et al. J Invest Dermatol. 2023;143(5):762-776.e3.
- Ishimoto T, et al. Front Immunol. 2024:15:1374581.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« Using advances in the genetics of psoriatic disease to better predict treatment response Next Article
How close are we to personalised medicine in psoriatic arthritis? »
« Using advances in the genetics of psoriatic disease to better predict treatment response Next Article
How close are we to personalised medicine in psoriatic arthritis? »
Table of Contents: IFPA 2024
Featured articles
Multiple novel oral agents show promise in psoriasis
Advances in psoriasis treatment: topical therapies show promising results
Personalised Medicine and Genetics in Psoriatic Disease
How close are we to personalised medicine in psoriatic arthritis?
Genetic and immunological advances in risk assessment and treatment of psoriatic diseases
Using advances in the genetics of psoriatic disease to better predict treatment response
Comorbidities and Complications in Psoriatic Disease
Depression complicates the management of psoriatic disease
The unfavourable role of obesity in psoriatic disease
Managing obesity and fibromyalgia in psoriatic disease
Advances in Psoriasis Treatment
Multiple novel oral agents show promise in psoriasis
Biologics for psoriasis: towards oral therapies and less frequent dosing
Advances in psoriasis treatment: topical therapies show promising results
Special Populations and Psoriatic Disease
Improving outcomes in pregnancy and psoriatic disease
Towards prevention of psoriatic arthritis in patients with psoriasis
Diagnostic Challenges and Disease Management
Itch and pain are major components of psoriatic disease and require management
Can diet help with the management of psoriasis?
Biologics in psoriatic arthritis: where we are and where we are headed
Related Articles
January 14, 2022
Selective IL-23 inhibition: a new option in active PsA
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com